Latest news

Monument Therapeutics and BDD Launch First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia

Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease

Latest blog posts

Eliminating Unnecessary Steps with Lean Clinical Development™

MCC Propellant Testing. CPHI & PODD conferences.